What's Happening?
Osita Chidoka, a former Aviation Minister and Chancellor of the Athena Centre for Policy and Leadership, has called on Nigerian pharmaceutical manufacturers to abandon a culture of excuses and adopt global quality standards. Speaking at the 29th national
conference of the Association of Industrial Pharmacists of Nigeria in Ilorin, Chidoka highlighted the industry's heavy reliance on imported Active Pharmaceutical Ingredients (APIs), which account for 70-80% of the sector's needs. This dependency is seen as a structural weakness that threatens affordable healthcare and economic resilience. Chidoka emphasized the need for manufacturers to exceed basic compliance with local regulations and align with international standards to improve product quality and gain market access.
Why It's Important?
The call for Nigerian pharmaceutical manufacturers to adopt global standards is significant as it addresses the industry's structural weaknesses and aims to enhance the country's health security and industrial competitiveness. By reducing dependency on imported APIs, the industry could lower costs and improve access to medicines, benefiting consumers and the economy. Aligning with international standards could also open up new markets under frameworks like the African Continental Free Trade Area, potentially boosting exports and economic growth. This shift could lead to increased investment in local manufacturing, job creation, and a more resilient healthcare system.
What's Next?
Chidoka's recommendations suggest a potential shift in the Nigerian pharmaceutical industry towards greater self-reliance and international competitiveness. Manufacturers may begin to invest in local production of APIs and other pharmaceutical components, reducing import dependency. This could involve partnerships with international firms and increased government support for local procurement. The industry might also see a push towards innovation and operational efficiency to meet global standards, which could attract foreign investment and enhance Nigeria's position in the global pharmaceutical market.
